Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $18

Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $18

Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $21 to $18.

byBenzinga Newsdesk

January 6, 2023

1 minute read

Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $21 to $18.

News

Paramount Global Announces Worldwide Expansion Of “EyeQ”

By Benzinga Newsdesk

November 1, 9:18 AM

Globally Unified Digital Video Advertising Platform Delivers Paramount's Massive Content Portfolio Through a Simple, Scaled Solution, Unmatched in Quality, Capabilities and Ad-Supported ReachNEW YORK, Nov. 1, 2023

PARA

News

A Look Into Financial Services Sector Value Stocks

By Benzinga Insights

February 1, 10:48 AM

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the…

CHMG

DA Davidson Downgrades Diebold Nixdorf to Neutral, Lowers Price Target to $3

By Benzinga Newsdesk

October 24, 9:17 AM

DA Davidson analyst Matthew Summerville downgrades Diebold Nixdorf (NYSE:DBD) from Buy to Neutral and lowers the price target from $5 to $3.

DBD

Analyst Ratings

What 7 Analyst Ratings Have To Say About Realty Income

By Benzinga Insights

September 21, 8:00 AM

Realty Income (NYSE:O) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $18

Related Posts

Paramount Global Announces Worldwide Expansion Of “EyeQ”

A Look Into Financial Services Sector Value Stocks

DA Davidson Downgrades Diebold Nixdorf to Neutral, Lowers Price Target to $3

What 7 Analyst Ratings Have To Say About Realty Income